Good afternoon, everyone. It is my pleasure to welcome you to the Neumora Therapeutics 2026 Annual Meeting of Stockholders. I am Paul Berns, Chairman and Chief Executive Officer. As previously announced, we are holding our annual meeting virtually and have stockholders attending via the web portal. Also here today are the other members of the company's Board of Directors, Kristina Burow, Matthew Fust, Alaa Halawa, Maykin Ho, and David Piacquad, and the executive officers of the company. Today's agenda for the meeting and a list of the rules of conduct for the meeting are available on your screen. In accordance with our bylaws, I will act as chair of this meeting, and Jason Duncan, our Chief Legal and Administrative Officer, will act as Secretary. Jim Raitt of American Election Services will act as Inspector of Elections. Today's meeting is being held pursuant to a notice included in the company's proxy statement and sent to Neumora stockholders on or about April 17th, 2026. I've been advised by our Inspector of Elections that a quorum is present. The virtual meeting is now called to order. We will now begin the formal business of the annual meeting and vote on the items presented in the proxy statement. It is 4:01 P.M. Eastern Time, and the polls are open. Stockholders who have voted by proxy need not vote again unless they wish to change their vote. If you have not already voted or you wish to change your vote, please complete a virtual ballot by clicking on the voting button on the web portal and following the instructions there. We will close the polls after the presentation of the proposals. The matters to be voted on at this meeting are listed in our proxy statement. The first item is the election of the Class III directors. The directors, if elected, will be elected to a three-year term or until their successors are duly elected and qualified. The following directors are standing for re-election: Paul Berns, Matthew Fust, and David Piacquad. The second item is the ratification of the Audit Committee's appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026. Ernst & Young has audited our financial statements for each fiscal year since the fiscal year ending December 31, 2019. The third item is an advisory vote on the compensation of our named executive officers. The fourth item is an advisory vote on the frequency of future advisory votes on the compensation of our named executive officers. That was the final proposal for today's meeting. Because no further business is on the agenda to come before this meeting, we will now take a brief pause for voting. With the time currently 4:03 P.M. Eastern Time, I declare the polls are now closed. I have been advised that the Inspector of Election has completed the preliminary vote count. The Inspector of Election has informed me that each of the named nominees for director have been duly elected. The selection of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31st, 2026, has been ratified. The compensation of our named executive officers, as disclosed in the proxy statement, has been approved on an advisory basis, and the frequency of future stockholder advisory votes on the compensation of our named executive officers is every year. The Inspector of Election will prepare a final report that will be included as part of the record of this meeting. The final voting results will be included in the company's current report on Form 8-K, to be filed with the Securities and Exchange Commission within four business days following this meeting. Thanks, Jason. We have no other business to conduct at this meeting. The meeting is now closed. I want to thank you all for coming to this year's virtual annual meeting. We appreciate your support of Neumora and look forward to providing you updates throughout the year. The meeting has now concluded. Thank you for joining, and have a pleasant day.